WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Balancing Sleep and Wakefulness: A Neuropharmacological Perspective

Pratiksha Belhekar [1], Pratiksha Bhalerao [2]

[1 2] Genba Sopanrao Moze College of Pharmacy, Wagholi, Pune-412207 Savitribai Phule Pune University, Pune

ABSTRACT:

Sleep Drug surfaced as a reputed field of clinical exploration in the ultimate half of the twentieth century. Over the once many decades, significant progress has been made in understanding the neurochemical mechanisms that regulate sleep and insomnia. This regulation involves a complex commerce of neuronal systems, neurotransmitters, and specialized brain capitals. Sleep- related issues are among the most frequent complaints encountered by croakers and psychiatrists. habitual sleep disturbances can significantly impact an existent's physical, internal, and social well- being, emphasizing the significance of specifics that impact sleep and insomnia. Sleep diseases are astronomically classified into wakefulness, hypersomnia, and parasomnia.

The medicines presently available generally work by either enhancing sleep- promoting pathways, similar as the GABAergic system (e.g., benzodiazepines and barbiturates), or stimulating insomnia- promoting systems, like the histaminergic, serotonergic 5- HT), and orexinergic systems. also, some medicines target other thrill- modulating mechanisms, similar as melatonin receptor agonists to promote sleep and adenosine receptor antagonists to promote insomnia.

Our gesture switches between being awake and asleep. Sleep itself has two main types REM (rapid-fire eye movement) sleep and non-REM sleep. These changes between being awake and asleep are controlled by complex processes in the brain. They're precisely managed by chemical couriers like glutamate, acetylcholine, adenosine, and dopamine. This review composition provides an overview of the medicines used in managing pathological sleep and insomnia countries, fastening on generally specified specifics and lately approved treatments.

Keywords: Wakefulness, NREM[Non-rapid eye movement], REM[Rapid eye movement], Sleep homeostasis, Acetylcholine, Adenosine, Dopamine, Opioids.

Introduction:

Sleep happens to play a vital part in the normal, healthy day to day conditioning of mortal beings. It's during this period that the mortal brain and the body work in sync to give the necessary rest and rehabilitation needed by an individual to be at the stylish of his capacities the coming day and the task that he intends to do. According to Stahl's text of essential related to psychiatry and is considered inversely important while assessing the psychiatric health of an existent.[1]

According to a study in the United States, about 60 million people suffer from longstanding problems related to sleep or insomnia. Though a definite number couldn't be set up in this regard for India, bone doesn't anticipate these figures to be veritably different. The control of sleep and insomnia involves numerous areas of the brain working together. In the history, scientists firstdiscovered that certain brain cells using monoamines and acetylcholine help keep us awake. More lately, experimenters have set up that other types of brain cells using GABA and glutamate also play important places in promoting sleep and insomnia. With new inheritable tools, scientists have learned that GABA- using neurons that help with deep (NREM) sleep are relatively complex. They have also set up that certain glutamate- using neurons in a part of the brainstem called the sublaterodorsal nexus are important for controlling REM sleep.[2]

Wakefulness:

Insomnia- In the awake state, the brain remains largely active, and the electroencephalogram (EEG) of the cerebral cortex shows a desynchronized pattern. This desynchronization occurs due to excitatory inputs from subcortical wake- promoting neurons. In pioneering studies from the 1940s, Maruzzi and Magoun linked that stimulating the region between the pons and midbrain convinced insomnia, leading them toname it the reticular cranking system. Since also, expansive exploration has explored these neuronal populations, theirthrusting pathways, and neurochemical characteristics, with findings proved in multitudinous review papers. [3-7]

Different wake- promoting neurotransmitters play distinct places in maintaining colourful aspects of insomnia. Acetylcholine is pivotal for cognitive functions, whereas noradrenaline contributes to attention- grabbing gests similar as novelty and stress, in addition to its part in cognition. also, orexin is essential for sustaining insomnia its absence leads to wakefulness and is also linked to motivated behaviours like eating and medicine dogging.

Dopamine, which regulates numerous motivated behaviours, also plays a part in insomnia, particularly in response to significant or salient stimulants. [8-13]

Recent exploration has discovered that both GABAergic and glutamatergic systems contribute to insomnia. Studies on the rudimentary forebrain (BF) indicate that cholinergic neurons don't directly promote insomnia but rather suppress cortical synchronization. rather, it's the GABAergic neurons in the BF that play a crucial part in cortical desynchronization and the conservation of insomnia.[14-17]

The part of the thalamus in insomnia remains batted. While large- scale lesions in the thalamus don't feel to impact overall sleep- wake duration, high-frequence optogenetic stimulation of specific thalamic neurons similar as calretinin- expressing neurons in the dorsomedial thalamus (DMT), paraventricular glutamatergic neurons, and ventromedial thalamic neurons has been shown to promote insomnia and increase locomotor exertion. still, utmost generally used general anaesthetics suppress cortico-thalamo-cortical exertion, pressing the involvement of this circuit in the process of arising from anaesthesia.[18-22]

NREM[Non-Rapid Eye Movement]:

When we fall asleep, the first major stage we enter is called NREM sleep (Non-Rapid Eye Movement sleep). This stage is marked by slow brain waves and a calm, restful state for the body. For a long time, scientists thought NREM sleep simply happened because the brain stopped receiving "stay awake" signals. But now, we know it's much more complex—there are special parts of the brain that actively create and maintain NREM sleep. [23-24]

One key player is a part of the brain called the ventrolateral preoptic area (VLPO), found in the front part of the hypothalamus. This area has special sleep-promoting neurons that release calming chemicals like GABA and galanin. These neurons turn on during sleep and help "switch off" areas of the brain that keep us awake. When scientists activated these neurons during experiments, they saw NREM sleep increases, REM sleep decreases and body temperature also decreases. This suggests that body cooling is a natural partof deep sleep, and the VLPO helps make that happen. [25-29]

We used to think that the deep brain controlled everything about sleep, including the brain waves seen during different sleep stages. But newer research shows that the cortex (the outer layer of the brain) also helps control sleep. Some special neurons in the cortex, like those that produce nitric oxide, help regulate how long and how deeply we sleep. Other types of neurons, like parvalbumin and somatostatin cells, help slow brain waves spread across the cortex. In short, the cortex doesn't just "receive" sleep—it helps direct it, too. Another important brain area is the parafacial zone (PZ). This region has neurons that also use GABA to promote deep, slow-wave sleep—the most restful part of NREM sleep. During this stage, the brain produces strong, slow delta waves that signal deep rest and healing. [30-33]

A chemical called adenosine also builds up in the brain the longer we're awake and makes us feel sleepy. It helps trigger NREM sleep by turning on sleep-related neurons in the VLPO and calming down the parts of the brain that keep us alert. Some key neurons in a brain area called the nucleus accumbens respond to adenosine and can start NREM sleep on their own. These neurons send "sleep now" signals to another region called the ventral pallidum. Adenosine also works in the striatum by calming down neurons that would normally keep us awake. [34-36]

The zona incerta (ZI), another region in the back of the hypothalamus, has special GABA-producing neurons that help with both NREM and REM sleep. These neurons may help 0% Plagiarized 100% Unique Characters:2979 Words:488 Sentences:27 Speak Time: 4 Min Page 1 of 2 us sleep by blocking signals from the brain's "wake-up" cells, like orexin neurons. [37]

Finally, there's a group of neurons in the brainstem—specifically in the rostro-ventral medullary reticular formation—that seem to be active only during NREM sleep. These neurons might help us move smoothly between being awake, NREM sleep, and REM sleep. But scientists still need to do more research to fully understand what they do.[38]

REM [Rapid Eye Movement]:

Sleep is a unique stage of sleep where the brain is very active almost like when we're awake but the body stays completely still. This stage was first discovered in humans, and soon after, similar patterns were found in animals like cats. In cats, REM sleep is known for showing brain activity combined with muscle paralysis, which is why it's often called "paradoxical sleep" (PS). The control ofREM sleep mainly involves specific neurons in the brainstem, divided into two types: REM-on (or PS-on) neurons that promote REM sleep, and REM-off (or PS-off) neurons that prevent it. A key areainvolved is the sublaterodorsal nucleus (SLD), also known as peri-LCα in cats [39,40].

The SLD contains glutamatergic (glutamate-using) neurons that are crucial for REM sleep. These neurons are split into two groups based on where they send signals. One group projects rostrally (toward the front) to the forebrain, where they help activate the cortex and produce theta brain waves in the hippocampus—important for memory and dreaming. The other group projects caudally (toward the back) to the ventromedial medulla (VM) and spinal motor neurons, where they help create muscle atonia, or the loss of muscle tone, which stops you from moving while you're dreaming. [41]

The SLD also contains some neurons that release GABA, a calming brain chemical. These GABA neurons help switch off the REM-off cells—those that normally prevent REM sleep. REM-off cells are spread across different parts of the brain and use various chemicals to do their job. For example, some use GABA, some use acetylcholine, others use noradrenaline, and some use serotonin. Their main role is to block the REM-on cells so that REM sleep doesn't happen at the wrong time. [42]

New research shows that the hypothalamus also helps regulate REM sleep. Specifically, neurons in the dorsomedial hypothalamus that produce GABA and galanin, and melanin concentrating hormone (MCH) neurons in the lateral hypothalamus, play a role[43,44]

The ventromedial medulla (VM) is also involved, although scientists are still learning exactly how in rats, when the VM is damaged or its signals are blocked, the animal still enters REM sleep, but without the normal muscle paralysis. In mice, certain VM neurons can actually trigger REM sleep when activated. [45–47]

Sleep homeostasis and the timing of sleep and wakefulness:

It's commonly known and backed by science that sleep is controlled by the body's need to stay balanced (homeostasis). The longer you stay awake, the sleepier you get and the more your body needs sleep. Not getting enough sleep affects how you think, and if you go without sleep for too long, it can seriously harm your body and even lead to death.[48]

The "two-process model" of sleep explains how our sleep is controlled by two systems: Process S (sleep pressure) and Process C (our internal body clock or circadian rhythm). Process S builds up the longer we are awake, creating a need for sleep. But sleep only happens when Process C says it's the right time, basedon our daily rhythm. Though simple, this model does a good job of explaining when we sleep and wake up in both humans and animals. [49,50]

During NREM sleep, the brain shows slow waves in the delta range (0.5–4.0 Hz), caused by interactions between the thalamus and cortex. These slow waves (called NREM delta power or EEG slow wave activity) increase the longer you stay awake. In contrast, sleeping—whether a nap or overnight—reduces this activity, showing that the need for sleep (Process S) is going down. Interestingly, this delta activity isn't much affected by your body clock (circadian rhythm). Because of this, it's seen as a good sign of how much the brain needs to recover from being awake and is often used to measure Process S.[49,51,52]

Biology of sleep and wakefulness:

How the Body Controls Wakefulness and Sleep:

Our brain stays awake with the help of five important chemicals: histamine, dopamine, norepinephrine, serotonin, and acetylcholine. These work together in a system called the ascending reticular activating system (ARAS), which keeps us alert. If this system doesn't work properly, it can cause sleepiness.

Our sleep is also controlled by two things: the circadian rhythm (our 24-hour body clock) and the sleep drive (our body's need for sleep). As the day goes on, we get more tired, and the sleep drive increases. When we rest at night, it decreases. A chemical called adenosine helps with this—it builds up during the day and drops while we sleep.

Histamine, made in a part of the brain called the TMN (tuberomammillary nucleus), keeps us awake. It works by stimulating the brain and blocking the VLPO(ventrolateral preoptic nucleus), which helps start sleep.

At night, the effect of the circadian rhythm fades, and the VLPO becomes active. This causes the brain to release GABA, a chemical that blocks the TMN and histamine, helping us fall asleep. [53,54]

Drugs affecting of sleep and wakefulness:

Acetylcholine:

Acetylcholine was the first neurotransmitter discovered. Early theories about sleep correctly suggested that acetylcholine is important for keeping the brain active during both wakefulness and REM (Rapid Eye Movement) sleep. However, drugs that affect acetylcholine are not commonly used to treat sleep disorders. Still, it's important to understand how acetylcholine helps control REM sleep, especially because it interacts with other brain chemicals that are targeted by sleep medications, like GABA and monoamines. Most studies about how acetylcholine affects sleep focus on its action through muscarinic receptors. There are five types of these receptors (M1 to M5), and the M2 receptor is especially important for starting REM sleep. [55-57]

The brain gives off the most acetylcholine in the basal forebrain when you are in REM sleep, a bit less when you are quietly awake, and the least when you are in deep, NREM sleep. More acetylcholine is released in the brain's cortex when you're awake or dreaming (REM sleep) compared to when you're in deep, non-dreaming sleep (NREM sleep). This shows that acetylcholine helps activate the brain during both waking and REM sleep states.[58-61]

Adenosine:

Adenosine is formed when ATP, the energy source of cells, breaks down. When we stay awake for a long time, adenosine levels rise in the parts of the brain that have been working hard. Studies show that during sleep, ATP levels go back up in those same brain areas. This supports the idea that sleep helps the brain recover and restore its energy.[62,63]

In humans, taking caffeine before bedtime makes it harder to fall asleep and reduces how well we sleep. Even drinking caffeine in the morning can lead to less and poorer sleep at night. Currently, there are no drugs that directly activate adenosine to help with sleep. However, adenosine is important in sleep medicine because substances like caffeine and theophylline, which block adenosine, can cause insomnia. Interestingly, adenosine may also help reduce pain, which could be useful in medical treatments.[64-66]

Staying awake for a long time causes adenosine levels to rise mainly in the basal forebrain and the cortex. It also increases the activity of adenosine A1 receptors in both humans and rats. When adenosine levels are boosted in the basal forebrain, or A1 receptor activators are given there, it leads to more sleep. On the other hand, blocking A1 receptors in this area reduces deep sleep and the amount of non-REM sleep. Studies show that the basal forebrain has A1 receptors, but not A2A receptors.[67-73]

Dopamine:

Stimulant drugs like amphetamine, cocaine, and methylphenidate help people stay awake and reduce excessive sleepiness by increasing dopamine levels in the brain. Studies show that being sleep-deprived also raises dopamine levels in humans. The brain cells that release dopamine and help with staying awake are mainly found in the ventral tegmental area (VTA) and the substantia nigra. These dopamine neurons send signals to several areas involved in sleep and wakefulness, including the basal forebrain, thalamus, and others. There are also dopamine-producing cells in another brain region called the ventrolateral periaqueductal gray, which are active when we're awake and connect with sleep-related areas. [74-76]

Opioids:

Opioids are commonly used to treat both short-term and long-term pain. Opioids can disturb the sleep pattern. Poor sleep can make pain feel worse, which may lead to needing higher doses of opioids for pain relief. Even in healthy people, normal doses of opioids can interfere with sleep.[77-81]
Opioids can mess with your REM sleep because they lower the amount of acetylcholine, a brain chemical released in a part of the brain called the pontine reticular formation, which helps control dreaming and deep sleep. They also lower the levels of adenosine in the basal forebrain and the same brain region, both of which normally help promote sleep. When morphine is directly given into the pontine reticular formation in animals like cats and rats, it leads to more wakefulness and less REM sleep.[77,78,82,83]

Glutamate:

Glutamate is the main chemical that excites nerve cells in the brain. Even though glutamate plays a major role in brain activity, scientists still don't fully understand how it controls sleep and wakefulness. The levels of glutamate in the brain change depending on whether we're awake or asleep, and these changes are different in various brain regions.
Glutamatergic neurons (neurons that use glutamate as a messenger) are found in a part of the rat brain called the pontine reticular formation. These neurons can produce and use glutamate to send signals. Glutamate causes these neurons to become more active (excited). In this brain region, glutamate and another chemical messenger, acetylcholine, work together and can strongly affect behaviour, such as causing catalepsy (a state where the body becomes rigid and unresponsive).
When substances that activate AMPA, kainate, or NMDA receptors are given separately, they all cause an excitatory effect on these neurons. But when drugs like ketamine or MK-801, which block NMDA receptors, are delivered into this area in cats, they reduce the release of acetylcholine and interfere with normal breathing.[84,85,86-90]

Conclusion:

Sleep is not just rest, it's a vital biological process deeply connected to our mental, physical, and emotional health. Over the years, science has revealed that sleep and wakefulness are carefully regulated by a complex interplay of brain regions and chemical messengers like GABA, glutamate, adenosine, dopamine, and acetylcholine. These systems work together to maintain our natural sleep-wake cycle, also influenced by internal body clocks and the buildup of "sleep pressure" over time.
Modern research has expanded our understanding of how different parts of the brain control REM and non-REM sleep, and how disruptions in these systems canlead to sleep disorders. Drugs that influence these brain chemicalswhether to promote wakefulness or enhance sleephave become important tools in managing conditions like insomnia, narcolepsy, and excessive daytime sleepiness.
However, while medications can help, they often come with side effects and must be used carefully. This makes it crucial to continue research in sleep neuroscience and drug development, aiming for safer, more targeted treatments. Ultimately, understanding how and why we sleep brings us closer to improving not just how long we sleepbut how well we live.

REFERENCE:

1. Stahl SM. Stahl's essential psychopharmacology: neuroscientific basis and practical application. 4th Ed. New York, Cambridge University Press; 2013:444- 471.
2. Killgore WDS, Killgore DB, Day LM, Li C, Kamimori GH, Balkin TJ. The effects of 53 hours of sleep deprivation on moral judgement. Sleep 2007;30(3):345-52.
3. Scammell TE, Arrigoni E & Lipton JO Neural Circuitry of Wakefulness and Sleep. Neuron 93, 747– 765, doi:10.1016/ j.neuron.2017.01.014 (2017). [PubMed: 28231463]
4. .Eban-Rothschild A, Appelbaum L & de Lecea L Neuronal Mechanisms for Sleep/Wake Regulation and Modulatory Drive. Neuropsychopharmacology 43, 937–952, doi:10.1038/npp.2017.294 (2018). [PubMed: 29206811]
5. .Jones BE Arousal and sleep circuits. Neuropsychopharmacology, doi:10.1038/s41386-019-0444-2 (2019).
6. Saper CB & Fuller PM Wake-sleep circuitry: an overview. Curr Opin Neurobiol 44, 186–192, doi:10.1016/j.conb.2017.03.021 (2017). [PubMed: 28577468]
7. Brown RE, Basheer R, McKenna JT, Strecker RE & McCarley RW Control of sleep and wakefulness. Physiol Rev 92, 1087–1187 (2012). [PubMed: 22811426]
8. Ballinger EC, Ananth M, Talmage DA & Role LW Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline. Neuron 91, 1199–1218, doi:10.1016/ j.neuron.2016.09.006 (2016). [PubMed: 27657448]
9. Borodovitsyna O, Flamini M & Chandler D Noradrenergic Modulation of Cognition in Health and Disease. Neural Plast 2017, 6031478, doi:10.1155/2017/6031478 (2017). [PubMed: 28596922]

10. Arrigoni E, Chee MJS & Fuller PM To eat or to sleep: That is a lateral hypothalamic question. Neuropharmacology 154, 34–49, doi:10.1016/j.neuropharm.2018.11.017 (2019). [PubMed: 30503993]
11. Nevarez N & de Lecea L Recent advances in understanding the roles of hypocretin/orexin in arousal, affect, and motivation. F1000Res 7, doi:10.12688/f1000research.15097.1 (2018).
12. Oishi Y & Lazarus M The control of sleep and wakefulness by mesolimbic dopamine systems. Neurosci Res 118, 66–73, doi:10.1016/j.neures.2017.04.008 (2017). [PubMed: 28434991]
13. Cho JR et al. Dorsal Raphe Dopamine Neurons Modulate Arousal and Promote Wakefulness by Salient Stimuli. Neuron 94, 1205–1219 e1208, doi:10.1016/j.neuron.2017.05.020 (2017). [PubMed: 28602690]
14. Kroeger D et al. Cholinergic, Glutamatergic, and GABAergic Neurons of the Pedunculopontine Tegmental Nucleus Have Distinct Effects on Sleep/Wake Behavior in Mice. J Neurosci 37, 1352– 1366, doi:10.1523/JNEUROSCI.1405-16.2016 (2017). [PubMed: 28039375]
15. .Anaclet C et al. Basal forebrain control of wakefulness and cortical rhythms. Nat Commun 6, 8744, doi:10.1038/ncomms9744 (2015). [PubMed: 26524973] ** This study is the first showing that wakefulness can be promoted by GABAergic neurons. This study also showed that despite the traditionally held belief to the contrary, basal forebrain cholinergic neurons do not actively promote wakefulness.
16. Chen L et al. Basal Forebrain Cholinergic Neurons Primarily Contribute to Inhibition of Electroencephalogram Delta Activity, Rather Than Inducing Behavioral Wakefulness in Mice. Neuropsychopharmacology 41, 2133–2146, doi:10.1038/npp.2016.13 (2016). [PubMed: 26797244]
17. Kim T et al. Cortically projecting basal forebrain parvalbumin neurons regulate cortical gamma band oscillations. Proc Natl Acad Sci U S A 112, 3535–3540, doi:10.1073/pnas.1413625112 (2015). [PubMed: 25733878]
18. Fuller P, Sherman D, Pedersen NP, Saper CB & Lu J Reassessment of the structural basis of the ascending arousal system. J Comp Neurol 519, 933–956 (2011). [PubMed: 21280045]2
19. Matyas F et al. A highly collateralized thalamic cell type with arousal-predicting activity serves as a key hub for graded state transitions in the forebrain. Nat Neurosci 21, 1551–1562, doi:10.1038/ s41593-018-0251-9 (2018). [PubMed: 30349105]
20. Honjoh S et al. Regulation of cortical activity and arousal by the matrix cells of the ventromedial thalamic nucleus. Nat Commun 9, 2100, doi:10.1038/s41467-018-04497-x (2018). [PubMed: 29844415]
21. Hudetz AG General anesthesia and human brain connectivity. Brain Connect 2, 291–302, doi:10.1089/brain.2012.0107 (2012). [PubMed: 23153273]
22. Ries CR & Puil E Mechanism of anesthesia revealed by shunting actions of isoflurane on thalamocortical neurons. J Neurophysiol 81, 1795–1801, doi:10.1152/jn.1999.81.4.1795 (1999). [PubMed: 10200213]
23. Cirelli C, Pompeiano M & Tononi G Fos-like immunoreactivity in the rat brain in spontaneous wakefulness and sleep. Arch Ital Biol 131, 327–330 (1993). [PubMed: 8250674]
24. Sherin JE, Shiromani PJ, McCarley RW & Saper CB Activation of ventrolateral preoptic neurons during sleep. Science 271, 216–219 (1996). [PubMed: 8539624]
25. Takahashi K, Lin JS & Sakai K Characterization and mapping of sleep-waking specific neurons in the basal forebrain and preoptic hypothalamus in mice. Neuroscience 161, 269–292 (2009). [PubMed: 19285545]
26. Szymusiak R, Alam N, Steininger TL & McGinty D Sleep-waking discharge patterns of ventrolateral preoptic/anterior hypothalamic neurons in rats. Brain Res 803, 178–188 (1998). [PubMed: 9729371]
27. Sherin JE, Elmquist JK, Torrealba F & Saper CB Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat. J Neurosci 18, 4705–4721 (1998). [PubMed: 9614245]
28. Kroeger D et al. Galanin neurons in the ventrolateral preoptic area promote sleep and heat loss in mice. Nat Commun 9, 4129, doi:10.1038/s41467-018-06590-7 (2018). [PubMed: 30297727]
29. Yoshida K, Li X, Cano G, Lazarus M & Saper CB Parallel preoptic pathways for thermoregulation. J Neurosci 29, 11954–11964, doi:10.1523/JNEUROSCI.2643-09.2009 (2009). [PubMed: 19776281]
30. Funk CM et al. Role of Somatostatin-Positive Cortical Interneurons in the Generation of Sleep Slow Waves. J Neurosci 37, 9132–9148, doi:10.1523/JNEUROSCI.1303-17.2017 (2017). [PubMed: 28821651]
31. Neske GT & Connors BW Distinct Roles of SOM and VIP Interneurons during Cortical Up States. Front Neural Circuits 10, 52, doi:10.3389/fncir.2016.00052 (2016). [PubMed: 27507936]
32. Breton-Provencher V & Sur M Active control of arousal by a locus coeruleus GABAergic circuit. Nat Neurosci 22, 218–228, doi:10.1038/s41593-018-0305-z (2019). [PubMed: 30643295]
33. Gent TC, Bassetti C & Adamantidis AR Sleep-wake control and the thalamus. Curr Opin Neurobiol 52, 188–197, doi:10.1016/j.conb.2018.08.002 (2018). [PubMed: 30144746]
34. Lazarus M, Oishi Y, Bjorness TE & Greene RW Gating and the Need for Sleep: Dissociable Effects of Adenosine A1 and A2A Receptors. Front Neurosci 13, 740, doi:10.3389/ fnins.2019.00740 (2019). [PubMed: 31379490]
35. Oishi Y et al. Slow-wave sleep is controlled by a subset of nucleus accumbens core neurons in mice. Nat Commun 8, 734, doi:10.1038/s41467-017-00781-4 (2017). [PubMed: 28963505]
36. Yuan XS et al. Striatal adenosine A2A receptor neurons control active-period sleep via parvalbumin neurons in external globus pallidus. Elife 6, doi:10.7554/eLife.29055 (2017).
37. Liu K et al. Lhx6-positive GABA-releasing neurons of the zona incerta promote sleep. Nature 548, 582–587, doi:10.1038/nature23663 (2017). [PubMed: 28847002]
38. Sakai K Behavioural state-specific neurons in the mouse medulla involved in sleep-wake switching. Eur J Neurosci 47, 1482–1503, doi:10.1111/ejn.13963 (2018). [PubMed: 29791042]

39. Aserinsky E & Kleitman N Regularly occurring periods of eye motility, and concomitant phenomena, during sleep. Science 118, 273–274 (1953). [PubMed: 13089671]
40. Jouvet M & Michel F [Electromyographic correlations of sleep in the chronic decorticate & mesencephalic cat.]. C R Seances Soc Biol Fil 153, 422–425 (1959). [PubMed: 13663472]
41. Aserinsky E & Kleitman N Regularly occurring periods of eye motility, and concomitant phenomena, during sleep. Science 118, 273–274 (1953). [PubMed: 13089671] 71. Jouvet M & Michel F [Electromyographic correlations of sleep in the chronic decorticate & mesencephalic cat.]. C R Seances Soc Biol Fil 153, 422–425 (1959). [PubMed: 13663472]
42. Lu J, Sherman D, Devor M & Saper CB A putative flip-flop switch for control of REM sleep. Nature 441, 589–594 (2006). [PubMed: 16688184]
43. Chen KS et al. A Hypothalamic Switch for REM and Non-REM Sleep. Neuron 97, 1168–1176 e1164, doi:10.1016/j.neuron.2018.02.005 (2018). [PubMed: 29478915]
44. Kroeger D, Bandaru SS, Madara JC & Vetrivelan R Ventrolateral periaqueductal gray mediates rapid eye movement sleep regulation by melanin-concentrating hormone neurons. Neuroscience 406, 314–324, doi:10.1016/j.neuroscience.2019.03.020 (2019). [PubMed: 30890480] * This study esthabishes an anatomical link between forebrain and brainstem REM sleep promoting systems.
45. Chen MC et al. Ventral medullary control of rapid eye movement sleep and atonia. Exp Neurol 290, 53–62, doi:10.1016/j.expneurol.2017.01.002 (2017). [PubMed: 28077261]
46. Valencia Garcia S et al. Ventromedial medulla inhibitory neuron inactivation induces REM sleep without atonia and REM sleep behavior disorder. Nat Commun 9, 504, doi:10.1038/ s41467-017-02761-0 (2018). [PubMed: 29402935]
47. Weber F et al. Control of REM sleep by ventral medulla GABAergic neurons. Nature 526, 435– 438, doi:10.1038/nature14979 (2015). [PubMed: 26444238]
48. Rechtschaffen A, Gilliland MA, Bergmann BM, et al. Physiological correlates of prolonged sleep deprivation in rats. Science. 1983; 221(4606):182–184. [PubMed: 6857280]
49. Borbely AA. A twoprocess model of sleep regulation. Hum Neurobiol. 1982; 1(3):195–204. [PubMed: 7185792]
50. Daan S, Beersma DG, Borbely AA. Timing of human sleep: recovery process gated by a circadian pacemaker. Am J Physiol. 1984; 246:R161–183. 2 Pt 2. [PubMed: 6696142]
51. Yasenkov R, Deboer T. Circadian regulation of sleep and the sleep EEG under constant sleep pressure in the rat. Sleep. 2010; 33(5):631–641. [PubMed: 20469805]
52. Yasenkov R, Deboer T. Interrelations and circadian changes of electroencephalogram frequencies under baseline conditions and constant sleep pressure in the rat. Neuroscience. 2011; 180:212– 221. [PubMed: 21303684]
53. Stahl SM. Stahl's essential psychopharmacology: neuroscientific basis and practical application. 4th Ed. New York, Cambridge University Press; 2013:444- 471.
54. Barrett KE, Barman SM, Boitano S, Brooks HL. Ganong's review of medical physiology. 25th ed. New Delhi. Lange; 2016:504-535.
55. Jouvet M. The role of monoamines and acetylcholine-containing neurons in the regulation of the sleep-waking cycle. Ergeb Physiol 1972;64:166–307. [PubMed: 4403272]
56. Ishii M, Kurachi Y. Muscarinic acetylcholine receptors. Curr Pharm Des 2006;12:3573–3581. [PubMed: 17073660]
57. Baghdoyan HA, Lydic R. M2 muscarinic receptor subtype in the feline medial pontine reticular formation modulates the amount of rapid eye movement sleep. Sleep 1999;22:835–847. [PubMed: 10566902]
58. Sarter M, Bruno JP. Cortical cholinergic inputs mediating arousal, attentional processing and dreaming: differential afferent regulation of the basal forebrain by telencephalic and brainstem afferents. Neuroscience 2000;95:933–952. [PubMed: 10682701]
59. Vazquez J, Baghdoyan HA. Basal forebrain acetylcholine release during REM sleep is significantly greater than during waking. Am J Physiol Regul Integr Comp Physiol 2001;280:R598–R601. [PubMed: 11208592]
60. Marrosu F, Portas C, Mascia MS, et al. Microdialysis measurement of cortical and hippocampal acetylcholine release during sleep-wake cycle in freely moving cats. Brain Res 1995;671:329–332. [PubMed: 7743225]
61. Materi LM, Rasmusson DD, Semba K. Inhibition of synaptically evoked cortical acetylcholine release by adenosine: an in vivo microdialysis study in the rat. Neuroscience 2000;97:219–226. [PubMed: 10799754]
62. Dworak M, McCarley RW, Kim T, et al. Sleep and brain energy levels: ATP chages during sleep. J Neurosci 2010;30:9007–9016. [PubMed: 20592221]
63. Benington JH, Heller HC. Restoration of brain energy metabolism as the function of sleep. Prog Neurobiol 1995;45:347–360. [PubMed: 7624482]
64. Landolt HP, Dijk DJ, Gaus SE, et al. Caffeine reduces low-frequency delta activity in the human sleep EEG. Neuropsychopharmacol 1995;12:229–238.
65. Landolt HP, Werth E, Borbely AA, et al. Caffeine intake (200 mg) in the morning affects human and EEG power spectra at night. Brain Res 1995;675:67–74. [PubMed: 7796154]
66. Gan TJ, Habib AS. Adenosine as a non-opioid analgesic in the perioperativesetting. Anesth Analg 2007;105(2):487–494. [PubMed: 17646510]
67. Strecker RE, Moriarty S, Thakkar MM, et al. Adenosinergic modulation of basal forebrain and preoptic/anterior hypothalamic neuronal activity in the control of behavioral state. Behav Brain Res 2000;115:183–204. [PubMed: 11000420]
68. Porkka-Heiskanen T, Strecker RE, McCarley RW. Brain site-specificity of extracellular adenosine concentration changes during sleep deprivation and spontaneous sleep: an in vivo microdialysis study. Neuroscience 2000;99:507–517. [PubMed: 11029542]

69. Elmenhorst D, Meyer PT, Winz OH, et al. Sleep deprivation increases A1 adenosine receptor binding in the human brain: a positron emission tomography study. J Neurosci 2007;27:2410– 2415. [PubMed: 17329439]
70. Elmenhorst D, Basheer R, McCarley RW, et al. Sleep deprivation increases A1 adenosine receptor density in the rat brain. Brain Res 2009;1258:53–58. [PubMed: 19146833]
71. Porkka-Heiskanen T, Strecker RE, Thakkar M, et al. Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Science 1997;276:1265–1268. [PubMed: 9157887]
72. Thakkar MM, Winston S, McCarley RW. A1 receptor and adenosine homeostatic regulation of sleep-wakefulness: effects of antisense to the A1 receptor in the cholinergic basal forebrain. J Neurosci 2003;23:4278–4287. [PubMed: 12764116]
73. Basheer R, Halldner L, Alanko L, et al. Opposite changes in adenosine A1 and A2A receptor mRNA in the rat following sleep deprivation. Neuroreport 2001;12:1577–1580. [PubMed: 11409719]
74. Boutrel B, Koob GF. What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. Sleep 2004;27:1181–1194. [PubMed: 15532213]
75. Volkow ND, Wang G-J, Telang F, et al. Sleep deprivation decreases binding of [11C]raclopride to dopamine D2/D3 receptors in the human brain. J Neurosci 2008;28:8454–8461. [PubMed: 18716203]
76. Monti JM, Monti D. The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev 2007;11(2):113–133. [PubMed: 17275369]
77. Nelson AM, Battersby AS, Baghdoyan HA, et al. Opioid-induced decreases in rat brain adenosine levels are reversed by inhibiting adenosine deaminase. Anesthesiology 2009;111(6):1327–1333. [PubMed: 19934879]
78. Lydic, R.; Baghdoyan, HA. Neurochemical mechanisms mediating opioid-induced REM sleep disruption. In: Lavigne, G.; Sessle, B.; Choinière, M., et al., editors. Sleep and Pain. Seattle: IASP Press; 2007. p. 99-122
79. Roehrs T, Hyde M, Blaisdell B, et al. Sleep loss and REM sleep loss are hyperalgesic. Sleep 2006;29:145–151. [PubMed: 16494081]
80. Chhangani BS, Roehrs TA, Harris EJ, et al. Pain sensitivity in sleepy pain-free normals. Sleep 2009;32:1011–1017. [PubMed: 19725252]
81. Lavigne, G.; Sessle, BJ.; Choinière, M., et al., editors. Sleep and Pain. Seattle, WA: International Association for the Study of Pain; 2007.
82. Keifer JC, Baghdoyan HA, Lydic R. Sleep disruption and increased apneas after pontine microinjection of morphine. Anesthesiology 1992;77:973–982. [PubMed: 1443752]
83. Watson CJ, Lydic R, Baghdoyan HA. Sleep and GABA levels in the oral part of rat pontine reticular formation are decreased by local and systemic administration of morphine. Neuroscience 2007;144:375–386. [PubMed: 17055662]
84. Lydic R, Baghdoyan HA. Ketamine and MK-801 decrease acetylcholine release in the pontine reticular formation, slow breathing, and disrupt sleep. Sleep 2002;25:615–620.
85. Stevens DR, McCarley RW, Greene RW. Excitatory amino acid-mediated responses and synaptic potentials in medial pontine reticular formation neurons of the rat in vitro. J Neurosci 1992;12:4188–4194. [PubMed: 1279137]
86. Kaneko T, Itoh K, Shigemoto R, et al. Glutaminase-like immunoreactivity in the lower brainstem and cerebellum of the adult rat. Neuroscience 1989;32:79–98. [PubMed: 2586753]
87. Jones BE. Arousal states. Front Biosci 2003;8:S438–S451. [PubMed: 12700104]
88. Núñez A, Buño W, Reinoso-Suárez F. Neurotransmitter actions on oral pontine tegmental neurons of the rat: an in vitro study. Brain Res 1998;804:144–148. [PubMed: 9729346]
89. Greene RW, Carpenter DO. Actions of neurotransmitters on pontine medial reticular formation neurons of cat. J Neurophysiol 1985;54:520–531. [PubMed: 2864403]
90. Elazar Z, Berchanski A. Glutamatergic-cholinergic synergistic interaction in the pontine reticular formation. Effects on catalepsy. Naunyn Schemiedbergs Arch Pharmacol 2001;363:569–576.